Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing?

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is suited for growth investing. Investors should of course do their own research, but we spotted CATALYST PHARMACEUTICALS INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

A Deep Dive into CATALYST PHARMACEUTICALS INC's Growth Metrics.

• The Return on Equity(ROE) of CPRX is 22.52%, which is a strong number. This indicates the company's ability to generate favorable returns for shareholders and reflects its effective management of resources.
• CPRX has consistently exceeded EPS estimates in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
• CPRX has demonstrated strong 1-year revenue growth of 23.47%, reflecting revenue momentum and its ability to generate consistent top-line expansion. This growth underscores the company's strong market position and its potential for future success.
• CPRX has demonstrated strong q2q revenue growth of 28.26%, suggesting a favorable trend in the company's financials and indicating the potential for continued expansion.
• CPRX has shown positive growth in its operating margin over the past year, indicating improved operational efficiency. This growth highlights the company's ability to effectively manage costs and maximize profitability.
• CPRX has experienced notable growth in its free cash flow (FCF) over the past year, signaling improved cash generation and strong financial performance. This growth suggests the company's ability to generate excess cash for reinvestment or shareholder returns.
• CPRX has shown positive momentum in its earnings per share (EPS) on a quarter-to-quarter (Q2Q) basis, with a 41.94% increase. This reflects the company's successful execution of its business strategies and its commitment to delivering improved financial results.
• The average next Quarter EPS Estimate for CPRX has experienced a 16.89% change in the last 3 months, reflecting evolving expectations by analysts regarding the company's EPS performance.
• Over the past year, CPRX has demonstrated %EPSYGROWTHTTM% growth in EPS, signifying its positive financial trajectory and potential for future profitability.
• The earnings per share (EPS) growth of CPRX is accelerating: the current Q2Q growth of 41.94% is above the previous year Q2Q growth of 40.91%. Earnings momentum and acceleration are key for high growth systems.

What else is there to say on the fundamentals of CPRX?

ChartMill utilizes a proprietary algorithm to assign a Fundamental Rating to every stock. This rating, ranging from 0 to 10, is computed daily by analyzing a variety of fundamental indicators and properties.

CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 570 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. These ratings could make CPRX a good candidate for value and growth and quality investing.

For an up to date full fundamental analysis you can check the fundamental report of CPRX

More ideas for growth investing can be found on ChartMill in our Lois Navellier screen.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.